Skip to main content
GILD $166.43 -0.06%
GILD logo
GILD · Gilead Sciences, Inc.
Track GILD — free
Market Cap
$206.43B
Shares
1.24B
Volume · Nov 20 7.59M Avg daily vol (3M) 5.99M
All webcasts

Conference · 2026-11-17

Gilead Sciences, Inc. (GILD) November 17, 2026 Conference Transcript

Concluded Nov 17, 2026 Audio replay
Nov 17, 2026 32:57 75 turns
Period
2026-11-17
Runtime
32:57
Sources
2 artifacts

Transcript & audio

32:57 Audio
Michael Yee Analyst — UBS

Good morning, everyone. Thank you for joining me on this next panel. I'm Michael Yee, Senior Biotechnology Analyst at UBS, and I'm very thrilled to have up on stage with us Andy Dickinson, who's the Chief Financial Officer of Gilead. Andy, congratulations on all the success this year. Your stock's at an all-time high. And we were just talking about the strategy on how you've put the story together, and you're sitting at a particularly unique time here with a lot ahead.

Yeah, absolutely. It's a very exciting time. First of all, thank you for having us. We appreciate your support. It's great to be here. And it is a very exciting time for the company. I mean, we've really spent the better part of the last decade rebuilding the company, rebuilding the pipeline, and you're really starting to see all that come through both in commercial launches with three more commercial launches coming behind three that are underway and then a really strong portfolio below it. So it's an exciting time for everyone at Gilead and for our shareholders. Absolutely.

Michael Yee Analyst — UBS

So, one of the unique things about Gilead is that you essentially have no meaningful patent expiry or no LOE issues for the next five years.

Really the next decade. Really the next decade, okay. Yeah, through 2036 with Biktarvi, yeah.

Michael Yee Analyst — UBS

And recently, your stock has been driven by the growth of HIV, and particularly not only through Biktarvi, but through PrEP. And so may I just start with the launch of Yaz2Go in PrEP, and can you tell us a little bit about how you feel about that success this year and how we should be thinking about the Yaz2Go and PrEP market?

Sure, yeah. So just a step back for everyone in the room and that's listening. Yes, Tugo is a once-every-six-month subcutaneous injection for HIV prevention. The phase three studies read out a couple years ago, these are called the purpose studies, phenomenal efficacy and safety that showed almost in one study at 100% prevention of HIV transmission across a very large group of people at risk of getting HIV, and the other study was 98%, 99% effective. It's a really transformative medicine that has raised awareness of HIV prevention. So we've had HIV preventions available for the last 10 years. We had two daily oral pills. The first one was Truvada, approved a decade ago. Descovy was approved, which is the current brand of daily oral that is a large part of our business and that we'll talk about, approved maybe five years ago. But it was really this long-acting injectable that raised awareness. And so the Yes2Go launch, which started a little bit over a year ago, is gone as well as we could expect. We're targeting a billion dollars of sales this year. That's an increase from our guidance at the beginning of the year. If I remember correctly, it was approximately $800 million of sales. And then maybe, Michael, to your question, the most important thing is that all the major launch metrics that we look at are tracking at or ahead of expectations. So to give you a couple of examples, we are seeing more people naive to HIV prevention starting on Yaz2Go than we would have expected. I think the expectation at launch is that you'd see people that were using the daily orals move, and we are seeing that about, you know, two-thirds to three-quarters of the people that are moving to Yaz2Go are coming off of the daily orals, but we're seeing a lot more people that are naive to HIV prevention starting on Yaz2Go, which is fantastic. And then the other thing is that we're seeing more people move off of generic Truvada. So in the switch population, you're seeing a much higher percentage of people moving off the generics onto the branded therapies, which is another really good indication. So, you know, when you put it all together, we're off to a great start, and we think it's a meaningful growth opportunity for us as we grow the prep business over the coming decades.

Michael Yee Analyst — UBS

How has compliance been? How does the durability of this market look like going forward?

Yeah, the durability of the market looks great. Compliance has been really, really strong. So when you think about compliance, or we call it persistence, you know, people coming back for their second shot in the HIV prevention market, these are not people that have HIV. So by definition, you know, the persistence or compliance in HIV prevention is going to, there are going to be people coming in and out of therapy over time. If they're in a monogamous relationship, they may not need HIV prevention, et cetera. So we're at more than 70% persistence for people coming back for their second shot, which is, again, to your earlier question about kind of launch indicators, higher than we would have expected. We expected very strong persistence. It's even been stronger than we expected a launch, which is another good thing. And then the final piece of the puzzle here is that when you think about our HIV prevention business, we have the leading daily oral in Discovy. We have Yes2Go, which is going to be about a billion in sales this year. Discovy is going to be about three billion in PrEP sales. So just today, our HIV prevention business is a $4 billion business. The market's growing at 14% to 15% in terms of volume in the last couple of years and going forward. And then we have two more launches in HIV prevention coming up that are very exciting. Early next year, we have a weekly oral version of Yes2Go, and then in 2028, we have a yearly intramuscular injection that are coming. So if you kind of fast forward 18 months from now, we will have four branded prevention therapies that will serve all the needs of people that are at risk of getting HIV and give them a lot of flexibility. And the fascinating thing, Michael, is that they can kind of move in and out of these. So, you know, if you're going on vacation, you can get a prescription for the weekly oral Yes2Go and use that for two months and then come back and get your every six-month injection or maybe your annual injection. So I think we're entering a new period of flexibility in a very rapidly evolving and growing market.

Michael Yee Analyst — UBS

So the PrEP market has been essentially all daily orals. And the market recently saw the launch of this injectable. Correct. Now, not everybody wants an injectable. Now, my understanding from survey work, you've done your own survey, we did survey work, you know, about 25% to 30% of people who are on these daily pills would say, okay, yeah, long-acting is important, it's an injectable. Not everybody wants an injectable. So I think survey work has supported 70% of people happy with daily oral pills. Now, the 30% of the market can be a multi-billion dollar drug. Like you said, Yaz2 goes at a billion and growing. And this weekly pill coming in February, Pedufa date?

Yes, exactly.

Michael Yee Analyst — UBS

February, could go after the other 70% of people who don't want the injectable, but they want something better than dailies.

Yes.

Michael Yee Analyst — UBS

So doesn't this weekly oral go after a market that's like 2x bigger than Yaz2 go?

It does, and it's really exciting. But maybe just to kind of, to the underlying, the underlying, there's two things happening. There's going to be a short-term dynamic next year with the weekly oral, and there's a long-term dynamic. So let's start with the long-term. As the every-six-month injectable and then the every-year injectable are available, we believe that more and more of the market will move to the long-acting injectables over time. Whether you get to 50-50 or whether you get to more of the market wanting the injectables, we'll see. But as people are getting experience and as more and more people are on the injectables, we think the preferences will change when you're doing your survey work or doing our survey work over time. The nice thing, though, is that we're giving people at risk of getting HIV all of the alternatives. So whether 70% of the market wants an oral or 50% or less than 50%, the weekly oral is going to give them a really important opportunity. And then in the short term, what's exciting is that, as I mentioned earlier, about $3 billion of our sales today are Discovy sales, which is the daily oral. The other way to think about the prevention market is that almost 50% of the prevention market, not quite today with our Yes2Go launch, is generic today, right? So if the entire HIV prevention market today, which is mostly in the United States, was branded, it's already an $8 billion market and growing. And so what may be not fully appreciated yet is the weekly oral really has the opportunity when it's launched next year to transform the oral market and have people move off not only the daily oral branded Discovy to a weekly option, but also off the generic Truvada to a weekly option. So you have this low, what I would describe as a very clear opportunity to transform the daily oral market and to move more and more of the market from generic to branded therapies in a short period of time.

Michael Yee Analyst — UBS

For the financial analyst, this is an investor conference. So for institutional investors that are looking at, there's about 400,000 people that are on the daily pills.

It's about the same way. Well, maybe, I mean, today it's between 600,000 and 700,000 people are on PrEP. Most of them are on the daily pills. So probably worth the $400,000.

Michael Yee Analyst — UBS

40% of that is on branded Descovy. It has a fairly high gross to net. There's a lot of rebating going on with that, and it's a daily pill. And then most, the majority of the rest, is on a generic older Truvada, which you book zero revenues from. So if the dailies go to this new weekly pill, significantly more convenient, it is the weekly form of the capsid. It's Llanocaprovir.

And it will have the same brand name. Same brand name.

Michael Yee Analyst — UBS

For everyone following like Wagovi, you got to have the Cacrosomac at the Wagovi because everybody knows that. This will be the same Yaz Tugo brand name. Exactly. And if they swap, like, why would people be taking daily generics that, to be clear, in the United States, this United States market, it is a zero copay for Truvada. It's a zero copay for Descovy. It's a zero copay for Yes2Go. Part of why we have the strong launch, we have the prep market is protected and has a zero copay. That if you're taking the daily generics, why would you not swap to a weekly? Why would someone want to be taking a pill seven days a week versus one pill?

Yeah, I mean, that's a really good question, and I think you're right. I mean, the other thing that you see with the long actings, even a weekly, is you're going to get better efficacy. And this is maybe a really important part of the HIV prevention and treatment market. And our purpose studies that, again, I talked about that came out a couple years ago, really showed this in really striking terms. The daily oral pills, because people do not take, you know, whether you're on HIV treatment or HIV prevention, people are not taking their daily oral pills. So to put this in context, you know, the expected daily oral pills in prevention, people take maybe 50% of the time. Oftentimes, people were using them on demand. And so you get much better efficacy with the long-acting. The same thing will be true with the weekly oral, to your point. And then as we move into the longer-acting injectables, I mean, even the once-yearly injection should give you better outcomes than every six months because you guarantee that the 30% of people that are not coming back for their second shot now are still covered for another six months.

Michael Yee Analyst — UBS

Now, again, for the institutional investors out there, a lot of this just happened in terms of a development and awareness of this over the last six months. Because when I was listening to the Q2 earnings call, which was just in the summer, this is when this was actually announced that you were actually going to file on the weekly as to a pill. Like, I'm no analyst.

It was a surprise to the market.

Michael Yee Analyst — UBS

It was a surprise to the market, and no one has this in the analyst estimates. So the drug is not yet approved, but if you go look at the consensus estimates for 2027-28, there's not a significant revenue contribution that people have in their models. So if this is coming, analyst thinks it could be a big launch. That's our analyst opinion. It's not really in the numbers. And you're saying, or Joanna's saying, that this launch could be quite strong because it has the same zero-pay copay and the same payer contracts that are going to already be in place. Is that correct?

Yeah, that's all right. Exactly. And you have to remember, like in the United States, there are many of the clinics that are prescribing HIV medicines are 340B clinics. And their entire business model is based on branded therapies and the discount that they get on those branded therapies. That's an important piece of how you think about it. The best case study for the oral-to-oral switch is when you look at our launch of Discovy and HIV prevention, it may have been six years ago now or seven years ago, but we moved half of the market from Truvada to Discovy in a 15-month period before Truvada went generic. Half of the people that were on Truvada, and it was a much smaller market at the time.

Michael Yee Analyst — UBS

When one year, people, and I cover this document, when one year, people converted from one daily to the other daily. And now you got a daily to a weekly. Exactly. I mean, I think that would be like 50% conversion.

Well, I mean, we're not giving any guidance, but I do think that the oral-to-oral conversion versus an oral-to-long-acting injectable that requires a different treatment paradigm and more management of the process, it's just completely different. And so, again, maybe to step back, this is why I talk about the short-term dynamic in prevention versus the long-term dynamic. And it is important to say, I mean, we see the HIV prevention business as a long-term, steady, consistent, durable source of growth for us. You are going to have the short-term dynamic with the weekly oral launch. But, you know, the other thing that's worth mentioning, in the United States, the CDC believes that 2.2 million people should be on HIV prevention. As I said, 600,000, 650, maybe close to 700,000 people are on prevention today. So it's not even 50% penetrated. I mean, and we think that the 2.2 million people is probably an underestimate of the people that would benefit from PrEP, and that as you have more data and awareness, that's going to increase over time.

Michael Yee Analyst — UBS

And that's actually happened because there is, in the U.S., there is DTC advertising. Or Yez2Go for HIV PrEP awareness, and that's part of it's been growing. Also, even Discovy.

Yes.

Michael Yee Analyst — UBS

A pill that's been around for a while, that's been growing significantly.

Right. It all goes back to the every six-month data that came out a couple years ago really raised awareness. So even though HIV prevention drugs were available, they're incredibly efficacious. People either weren't aware of them or didn't want to use the daily pills, and so it's really grown that market.

Michael Yee Analyst — UBS

Last question on this. So this is a February PDUFA date, but I've never actually seen any data on the weekly pill. There's no phase three data. I've never seen a poster presentation. And so actually I was like, wait a second, is there any regulatory risk to the approval? Because I've actually never seen any data. Is this a PK bridging or is this actually the fact that this pill is the loading dose? of the injectables. Before you get the injectable, you get a loading.

That's exactly it. So it's a little more than that. And the reason that we didn't disclose this until last year is so some of you may remember that back in the early days of the lenocapivir development, the program was put on clinical hold after the phase three study started because the FDA had some questions on the glass vials. It had nothing to do with the drug, nothing to do with efficacy or safety. But when the program was put on clinical hold, patients that had already started the study were then bridged for some period of time on the weekly oral. So it's not just the loading dose. Within the purpose studies is a whole, you know, pocket of data and information on people that were on the weekly oral for an extended period of time. And that's why our team then, and we have a really bright regulatory and clinical development team, went to the FDA saying, we believe we have enough data to support the approval of the weekly oral, and we waited until we had the alignment with the FDA and the file was accepted before publicly disclosing it in the second quarter. So that's the background. The data exists, but it's within the purpose data.

Michael Yee Analyst — UBS

And it makes sense. And again, not everybody wants an injectable. 70% of the market, I think, wants a weekly, a pill. So that makes sense. That's right. All right. So you think it could be a fast conversion and there should be. Easy and similar reimbursement. So it could be a fast launch. Now, Joanna says publicly that it could be as fast of a launch as Tugo. Do you agree with that?

Well, I'm very bullish on this launch and excited about it, so I'm not going to give any more guidance beyond that, but, I mean, look, I believe our HIV prevention business with the, you know, two approved therapies and two more coming is going to be a source of exciting, durable, consistent growth for years and years to come.

Michael Yee Analyst — UBS

Okay. Launch number two. This is actually slightly earlier, so I'm sorry I jumped to that, but in December, so like in a couple weeks, but there's a December 30th. Pedufa date for Anita cell. 23rd, December 23rd. December 23rd, before Christmas. So Anita cell is a potential best in class BCMA car T. Um, tell us about this program, what you think the label will look like compared to the initial launch of Carvicti, and would this be a launch that is stronger than the Carvicti numbers at their launch?

I think it's going to be a very strong, very strong launch, and we really love the, the, um, you know, the, the, you know, cell profile, exactly. Just a step back, though, for everyone in the room. I mean, we have three launches that are underway now. Yaz Tugo is one of them in HIV prevention. We have an HIV treatment launch in Bix Lenvo, which is going to compete in the switch market, which is really exciting. And then we have Liv Delsey, a liver drug in PBC that's doing beautifully. Tridelvy just launched in first-line triple-negative breast cancer. So then you start, you move into what's coming. We have three more launches coming that will also drive growth. So the strong performance that you see in the business in the third quarter is the result of very strong core-based business and then all of these existing launches. So then you're going to layer on, in addition to what we just talked about with Yez2Go and the other launches, the HIV, I'm sorry, the anitocell launch at the end of this year. So anitocell is a CAR-T, BCMA CAR-T, that has very strong data in fourth line plus multiple myeloma, which is the largest heme oncology indication. And Carvicti, which is a... Competitor drug has been in the market for four years, I believe, maybe a little bit more, a little bit less. I believe it's annualizing at $2.8 billion of sales, and the vast majority of those sales are in the fourth line, plus the market that we're going to enter today. So most Carvicti use today is in those late-stage markets. If you look at the data from Aneedocel, and you're going to see more data presented at ASH, updated data, including the Kaplan-Meier curves that people have been asking for, which is exciting. We believe that we have a drug that shows at least as good of efficacy, if not better efficacy profile, but a meaningfully differentiated safety profile, which is really important. Some of the competitor regimens have shown the potential for long-term neurological toxicity. So Parkinson's-like disease or similar, very serious neurological conditions that don't go away, which have been an issue for the fourth line plus. Oh, it's in the label. It's in the label. It's in the label.

Michael Yee Analyst — UBS

So we know that neurological adverse events are a problem. It's in the black box. That's right. And you believe that your approval by December 23rd, you feel confident on that?

We do, yes. Okay, okay.

Michael Yee Analyst — UBS

And assuming that approval, that you will not have these neurological side effects in the label, but also that your label reflect a fourth line plus population, or VICTI, when it was approved, was a fifth line plus label indication. So by getting fourth line, that's a bigger market, and would go head to head against their launch.

Yeah, we expect a fourth line plus label, and we have not seen any signs of these neurological side effects. There are normal side effects of carotidin, what I call normal, CRS or short-term neurotox, but these long-term neurological side effects, there's another side effect with the competitive regimen as well that we don't expect to have. So we think we'll have a meaningful advantage on the safety. And then we also have the second line plus studies are fully enrolled. We'll have data next year in those studies. So we expect to have an EtoCell moving up in lines of therapy. And that's the big opportunity because the second line plus is about four times larger than the fourth line plus. This is Imagine 3. I believe it is Imagine 3, yes. And again, you know, our sense is the reason that you see the competitive regimen used predominantly in fourth line plus today is because of the side effect profile. And you wouldn't move it up into earlier lines because why would you

Michael Yee Analyst — UBS

put a second line myeloma patient? I mean, we do have good options in second line. So you wouldn't do that at the risk of getting cerebral palsy or Parkinsonian cases. So having a cleaner side effect and strong efficacy would be a more compelling option in second line.

That's exactly it.

Michael Yee Analyst — UBS

Now, how do I know the efficacy is as good? The competitor says that there's no PFS curves, and the PFS you're saying is coming at Ash? What is a good PFS number?

It should be the same or better? I'll let you determine that when you see the PFS curves at Ash, but I think we've said consistently that we believe we have a very competitive profile and one that will lead us to have, I mean, we've already said that we expected 18 months to have a majority of the market. And in CAR-T. So we've, you know, we expect to have very broad, you know, ATCs, these are authorized treatment centers, up and running at launch. It will then take a couple of months, up to six months, to get all of the formulary access at all of the major treatment centers. But, you know, by 18 months, we expect to be in a very strong position.

Michael Yee Analyst — UBS

The call that Carvicti did a couple hundred million dollars in their first 12 months. Now, when they did that, they were more manufacturing capacity constrained, not demand constrained. If you go back a couple years, every analyst was like, oh, how many doses can you actually be allowed to do? Because the FDA actually limited that. So they were selling out every slot, and they were doing a couple hundred million. You don't believe you would have that issue.

We don't expect to be limited by the FDA. You expect to do more than that. Yeah, we were not limited with our YesCarta and Tocardus launches, which are the two approved cell therapies that we market that we acquired from Kite Pharma. That wasn't the case. We have exceptional manufacturing. We have three global manufacturing facilities. We don't expect to have that limit. And again, we're not going to give guidance specifically on the launch beyond what we guided to in terms of very strong payer coverage at launch, very strong ATC coverage and ready to go. It will take one or two quarters to get the formulary access, but by the end of 18 months, we expect to have the leading CAR-T in Fourth Line Plus, and so that's a very exciting potential for us.

Michael Yee Analyst — UBS

All right. Well, when you think about those launches, Anita Cell, and you think about the weekly Yes2Go launch in February, I'll be thinking about 2027 guidance, because if the weekly Yes2Go pill could be hundreds of millions of dollars or a billion, I mean, that would be a factor in your guidance. So I'm sure you're thinking about guidance, but we are thinking about guidance.

I'm not going to give any guidance today. We will follow our practice of giving guidance on our, I would expect, on our end of year call, which happens at the end of January, early February. But, you know, look, we've seen really strong growth in the business. I mean, the other thing that you and I have talked about, I think as we've been rebuilding Gilead and the pipeline and building up, you know, to all of these launches and the diversification in our HIV business and the rest of the business, a lot of our growth in our base business has been masked by the decline of our COVID antiviral remdesivir, Veclory, which peaked at like 5.6 billion in sales. I think it was five years ago, and we'll have about $300 million in sales. So when you look at the base business, and going forward, the entire business, Veclory is so small now, it'll be much easier to see. But our base business has grown 7%, 8%, or 9% the last three years. This year, it's going to grow 10% to 11%. And we're just moving into this launch cycle. There will be a couple of things that impact the business. We disclosed on our third quarter call the expected $1.5 billion headwind in 2028 with the Big Tarby drug price negotiation. But, you know, we have so much growth coming in the business that even in 2028, with that $1.5 billion headwind, we expect the HIV business to grow. We expect our total business to grow. We expect our EPS to grow.

Michael Yee Analyst — UBS

So in 2026, excluding Veclary, you said the base business grew approximately 10%.

10% to 11% is what we expect for this year. 10% to 11% was what was in the last news call.

Michael Yee Analyst — UBS

That was an increase from the beginning of the year, which was like 8 to 10.

Significant increase. I think it was even 6%.

Michael Yee Analyst — UBS

Is there any one-time things that were there? I guess, obviously, the launch of Yez Tuga was one factor, but as you get into 2027, is there any reason that would be materially different? Shouldn't that be steady? Because now you need to sell and the weekly pill.

Yeah, I mean, the one thing I would call out, there has been some pricing favorability. You've seen exceptionally strong growth in the HIV business, both in the treatment business. Biktarvi grew, I think, in the third quarter 10% year-over-year, which is the leading treatment daily pill. There has been some pricing favorability, meaning, in particular, in HIV prevention. So as more of, especially Discovi, Discovi was approved for both treatment and prevention. As more and more of the Discovy sales are in prevention, the payer mix in prevention is completely different than the payer mix in treatment. Most patients on prevention in the United States are in large urban areas and have commercial insurance. So as more of that business has moved to prevention, you have more commercial coverage, which has been a pricing tailwind. At some point, you should expect that that will moderate, but the overall story doesn't change. There's very strong, most of the growth this year in HIV has been demand-led volume growth, and we expect to continue to see that. But to your question of, there has been some pricing favorability, whether it repeats or not remains to be seen. But, you know, when you kind of strip it all away, there are so many sources of growth in the business with the launches. We expect really strong demand-led volume growth, not only in our HIV business, but also in the other areas.

Michael Yee Analyst — UBS

So it should be somewhat in the range of the growth of 2026.

I'm not going to say that yet. You have to wait to see our guidance. But, you know, we have said that we expect to have very strong growth over that. I mean, again, it goes back. We don't have patent cliffs until 2036. There will be a couple of things like the drug price negotiation.

Michael Yee Analyst — UBS

Yeah, that's a one-time blip. That's a one-time blip.

Yep, yep. But, you know, when we kind of look at it, the setup for the next decade and I think beyond looks really good.

Michael Yee Analyst — UBS

I want to save the last couple of minutes because there are three new developments in your immunology pipeline that I think are important. In biotech, pharma, immunology is, I've got to be honest, one of the hottest spaces. You've got AbbVie, J&J, doing tremendously well in ulcerative colitis and IL-23s. Yes. You have AbbVie by an apogee and atopic dermatitis. These are, you know, $100 billion markets. And there's been a lot of IPOs as well in immunology. Now you have three programs in immunology, specifically small molecules and peptides. And so can you just briefly highlight in the last couple minutes, what you have in alpha four beta seven small molecule? Sure. IL-23 oral peptide. Yep. Everybody knows ICO. And an IRAC-4 that just put up positive lupus data.

Yeah. So maybe importantly, we have seven or eight programs in immunology that have been flying under the radar, both in cell therapy and in small molecules. The really exciting thing is we have some of the world's best chemists. We've always applied that in HIV. When our new CEO joined eight years ago and we all started working together, we really started applying that not only in oncology, but also in immunology. And so this has been kind of under the radar. Two of those programs have had data recently. So there's an oral alpha-4 beta-7 called Invistagrast. So for many of you that know the ulcerative colitis margus, Intivio is a $6 billion franchise for Takeda. It is an alpha-4 beta-7 antibody. We showed similar efficacy in a large phase two study for an oral daily pill that can be combined with other mechanisms. And equally importantly, the safety profile looked very good and gives it a real chance to be combined with other things.

Michael Yee Analyst — UBS

I'll put it was the efficacy was higher than Intivio, but we have a pill, but the middle dose showed low efficacy. What happened on the middle dose?

I mean, it's hard to say, right? I mean, you see this in studies. We don't see that as an issue. I mean, you see this in phase two studies at times. You saw such strong efficacy kind of across all three doses. We'll continue to look at the data.

Michael Yee Analyst — UBS

I cover AbbVie. We asked AbbVie and other leaders what they think about that. They just said, we care about endoscopy. I can't remember what the endoscopy results.

No, we saw absolute consistency across all of the other metrics in terms of the efficacy, so you can go back and look at the data from the, it was the conference in Europe. I'm forgetting the name off the top of my head.

Michael Yee Analyst — UBS

UEG.

We announced an acquisition of an IL-23 peptide that we expect to close later this year. Really interesting molecule out of China. It has the potential for monthly dosing as a monotherapy, but more importantly, it's so potent, And it looks like we have the potential to do a fixed-dose combination. Again, it's not certain, but the potential to do a fixed-dose combination with our oral alpha-4, beta-7. We will also, though, I should say, look at other partnerships for our alpha-4, beta-7. So just because we're acquiring our own IL-23 does not mean that we won't look at other partnerships, including with other IL-23s as well as other mechanisms. We see our oral alpha-4, beta-7 as something that could be used broadly. We've done this in our HIV business. As you know, historically, we did partnerships with BMS and J&J and others to develop...

Michael Yee Analyst — UBS

Hep C, HIV, oncology, you do collaborations to test what happens. IL-23, you have, you said monthly.

Well, it can be used as a monthly oral, it looks like. So in some of the derm indications, we could do monotherapy as a monthly oral, which could be exciting.

Michael Yee Analyst — UBS

Because we're aware of the hand-seal compound that went to Avere.

Right, and we followed that very closely. We know that team really well, as you know. So we looked at the entire space. We really like this molecule that we're acquiring. It was a competitive process. There was a lot of interest from large companies for good reason. And then the final one is our IRAC-4 small molecule inhibitor. We have two IRAC-4 in programs. One is a degrader that came from one of our partnerships outside, and we developed our own small molecule. At ACR last week, we presented the data in cutaneous lupus. 20 patients, 25 patients, three quarters on drug, a quarter on placebo. Really strong data in a very tough-to-treat indication.

Michael Yee Analyst — UBS

I got to be honest. This also flew under the radar. We wrote a note about this. We've been following other lupus programs, hosting a lupus call on Monday, by the way, next week. But Biogen stock is up huge this year, and part of it is on the lupus program, and Biogen has great litophilumab data in CLE. You have a pill, they have an injectable, and your CLE data actually did cross-trial comparison of phase 2, but placebo-controlled actually looked as strong or better than the litafilament.

Yeah, small phase 2A study, but it kind of matches what we expected. We're moving into the phase 2B. Maybe when you back up, Michael, to your point, there's just a lot of ways to win with where we're going. I mean, you've got the really strong HIV business, both treatment and growth, PrEP. We have more launches coming in both prevention and treatment. And Tridelby is doing beautifully, which we didn't talk about, which is the gold standard for triple negative breast cancer. That's, you know, Lived Delby's doing well.

Michael Yee Analyst — UBS

I mean, you've got tubular, tubular acquisition and ADC as well. So there's a lot there. So I think you need another R&D day. Andy, thank you very much for the discussion. Look forward to 2027 with you.

Thank you for your support. Thank you for having us.

Michael Yee Analyst — UBS

And everything ahead. So thank you.

Analyst Q&A · 1 question
Full-screen source Call document